Streetbeat News

AMIX

Autonomix Medical Inc.

Industry

Surgical and Medical Instrument Manufacturing

Open

3.17

Mkt cap

5.5M

Volume

82K

High

3.23

P/E Ratio

-0.16

52-wk high

152.00

Low

3.00

Div yield

N/A

52-wk low

3.00

Autonomix Medical, Inc. has successfully closed a $10 million underwritten public offering, including a partial exercise of the over-allotment option. This funding will support the company's focus on precision nerve-targeted treatments.

Portfolio Pulse from

November 25, 2024 | 9:15 pm

Autonomix Medical, Inc. has announced the pricing of a $9.0 million underwritten public offering, involving common stock units and pre-funded warrant units.

Portfolio Pulse from

November 22, 2024 | 2:30 pm

Autonomix Medical, Inc. reported its Q2 FY2025 financial results and provided a corporate update. The company is conducting a proof-of-concept clinical trial for pain associated with pancreatic cancer, showing promising preliminary results with 100% of the lead-in patient responder group ceasing opioid use 4-6 weeks post-procedure.

Portfolio Pulse from

November 11, 2024 | 1:15 pm

Several healthcare stocks experienced significant price movements during Friday's intraday session. Notable gainers included Athira Pharma, ChromaDex, and Theriva Biologics, while Lexicon Pharmaceuticals and Myriad Genetics were among the biggest losers.

Portfolio Pulse from Benzinga Insights

November 01, 2024 | 4:36 pm

The article highlights significant intraday movements in healthcare stocks, with Biofrontera, Autonomix Medical, Anavex Life Sciences, Aerovate Therapeutics, MiMedx Group, and Exicure seeing gains, while Matinas BioPharma, Anika Therapeutics, Psyence Biomedical, CalciMedica, Compass Pathways, and Vaccinex experienced losses.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 4:34 pm

Autonomix Medical shares rose after reporting positive topline 7-day data results from its first 15 patients, showing significant impact on pancreatic cancer pain treatment with maintained pain reduction, a 79% responder rate, no opioid use, and improved quality of life.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 12:56 pm

Autonomix Medical, Inc. (NASDAQ:AMIX) reported positive preliminary results from its clinical trial on treating pancreatic cancer pain. The trial showed a 79% responder rate with significant pain reduction and no opioid use, improving patients' quality of life.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 12:36 pm

The article highlights significant pre-market movements in healthcare stocks on Thursday. Notable gainers include Autonomix Medical, Tenon Medical, and Aerovate Therapeutics, while Matinas BioPharma and Equillium are among the biggest losers. Several companies reported Q3 earnings, impacting their stock prices.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 12:10 pm

Several healthcare stocks experienced significant price movements in Thursday's pre-market session. Notable gainers include Autonomix Medical, Tenon Medical, and Alphatec Holdings, while Matinas BioPharma and Equillium saw substantial declines.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 12:09 pm

U.S. stocks rose on Monday, with the Dow Jones, NASDAQ, and S&P 500 all gaining. Financials led the sectors, while energy lagged. Koninklijke Philips NV shares plunged 16% after missing Q3 earnings estimates and revising its 2024 outlook. Healthcare Triangle, Autonomix Medical, and Evoke Pharma saw significant stock price increases due to positive developments.

Portfolio Pulse from Avi Kapoor

October 28, 2024 | 7:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.